Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M113,994Revenue (TTM) $M22,928Net Margin (%)34.4Altman Z-Score2.7
Enterprise Value $M109,688EPS (TTM) $10.6Operating Margin %43.5Piotroski F-Score7
P/E(ttm)14.7Beneish M-Score-2.6Pre-tax Margin (%)40.9Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %12.8Quick Ratio4.1Cash flow > EarningsY
Price/Sales5.15-y EBITDA Growth Rate %20.3Current Ratio4.4Lower Leverage y-yY
Price/Free Cash Flow11.6y-y EBITDA Growth Rate %12.7ROA % (ttm)10.3Higher Current Ratio y-yN
Dividend Yield %2.8PEG0.7ROE % (ttm)26.3Less Shares Outstanding y-yY
Payout Ratio %39.0Shares Outstanding M735ROIC % (ttm)30.6Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AMGN is held by these investors:



AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patton Cynthia MSVP & CCO 2017-05-24Sell2,922$154.40.4view
Such Annette LouiseVP, Finance and CAO 2016-08-02Sell3,000$174.59-11.21view
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.120.58view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.99-1.89view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.21-1.4view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.485.82view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.840.76view
Hassan FredDirector 2015-08-19Buy3,010$166.63-6.97view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-14.07view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.06-1.31view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna May 23 2017 
    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amgen Inc. (AMGN) May 23 2017 
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMG May 22 2017 
    Osteoporosis Drug Meets Primary and Secondary Endpoints May 23 2017 
    Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Cu May 22 2017 
    Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab May 22 2017 
    Amgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference May 12 2017 
    Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® May 02 2017 
    Amgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease Apr 27 2017 
    The 4 Principles That Drive PRIMECAP Apr 27 2017 

    More From Other Websites
    3 Dividend Stocks That Thrive in Market Crashes May 27 2017
    SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amgen Inc. and Encourages... May 26 2017
    Glancy Prongay & Murray LLP Commences Investigation on Behalf of Amgen Inc. Investors May 26 2017
    Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote May 26 2017
    Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017 May 26 2017
    [$$] Harpoon Therapeutics Snares $45 Million Series B for Prostate Cancer Treatment May 25 2017
    These 5 Healthcare Stocks Are Undervalued May 25 2017
    Could There Be a Revenue Fall for Neulasta in 2017? May 25 2017
    A Look At Nvidia's Largest Shareholders And What Their Presence Means May 25 2017
    Short Sellers Raise the Stakes in Major Biotechs May 25 2017
    The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene May 25 2017
    Radius Health Osteoporosis Drug Positive in Phase III Study May 25 2017
    Exploring Kyprolis’s Revenue Trend in 2017 May 25 2017
    Drug approvals bounce back as R&D labs churn out new winners May 25 2017
    Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017 May 25 2017
    3 Reasons Gilead Sciences, Inc. Is a Better Dividend Stock Than Amgen, Inc. May 24 2017
    Third Avenue Continues to Buy Amgen, 8 Others May 24 2017
    Neupogen and Enbrel Could See Falling Revenues in 2017 May 24 2017
    Biosimilars Could Become a Key Long-Term Growth Driver for Amgen May 24 2017
    Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data May 24 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)